Capital & Planning LLC Trims Stock Holdings in Abbott Laboratories $ABT

Capital & Planning LLC lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 37.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,252 shares of the healthcare product maker’s stock after selling 6,208 shares during the period. Capital & Planning LLC’s holdings in Abbott Laboratories were worth $930,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Brown Lisle Cummings Inc. raised its stake in shares of Abbott Laboratories by 8.4% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 5,100 shares of the healthcare product maker’s stock valued at $463,000 after purchasing an additional 394 shares during the period. VELA Investment Management LLC grew its holdings in Abbott Laboratories by 164.1% during the 2nd quarter. VELA Investment Management LLC now owns 54,892 shares of the healthcare product maker’s stock valued at $4,981,000 after buying an additional 34,106 shares in the last quarter. Corient Private Wealth LP increased its position in shares of Abbott Laboratories by 9.1% during the second quarter. Corient Private Wealth LP now owns 1,818,488 shares of the healthcare product maker’s stock valued at $165,010,000 after buying an additional 151,301 shares during the period. Tucker Asset Management LLC increased its position in shares of Abbott Laboratories by 11.1% during the second quarter. Tucker Asset Management LLC now owns 3,467 shares of the healthcare product maker’s stock valued at $315,000 after buying an additional 345 shares during the period. Finally, HORAN Wealth LLC lifted its holdings in shares of Abbott Laboratories by 3.1% in the second quarter. HORAN Wealth LLC now owns 38,698 shares of the healthcare product maker’s stock worth $3,511,000 after buying an additional 1,161 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABT has been the topic of a number of analyst reports. TD Cowen upped their target price on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. The Goldman Sachs Group decreased their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Piper Sandler restated an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a research report on Thursday, August 13th. Finally, Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Stock Down 0.0%

ABT opened at $108.29 on Tuesday. The business’s fifty day simple moving average is $104.74 and its 200 day simple moving average is $100.00. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The stock has a market cap of $187.38 billion, a PE ratio of 35.05, a P/E/G ratio of 2.01 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the company posted $1.26 earnings per share. The company’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.